DXCM - DexCom, Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $0.48
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$85.82
DETAILS
HIGH:
$95.00
LOW:
$72.00
MEDIAN:
$87.00
CONSENSUS:
$85.82
UPSIDE:
17.42%
Market Cap:
28.51B
Volume:
3,540,336
Avg Volume:
5,316,658
52 Week Range:
54.11-91.87
Sector:
Healthcare
Industry:
Medical - Devices
Beta:
1.49
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
10,200
IPO Date:
2005-04-14
EPS (TTM):
2.14
P/E Ratio:
30.97
Revenue (TTM):
4.66B
Total Assets:
6.34B
Total Debt:
1.39B
Cash & Equiv:
917.70M
Rev Growth (5Y):
19.3%
EPS Growth (5Y):
10.3%
FCF Growth (5Y):
31.3%
ROCE:
21.7%
Debt/Equity:
0.51
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $0.68 | $0.65 | +4.6% | $1.3B | $1.2B | +6.5% |
| 2025-10-30 | $0.61 | $0.58 | +5.9% | $1.2B | $1.2B | +2.2% |
| 2025-07-30 | $0.48 | $0.44 | +8.2% | $1.2B | $1.1B | +2.9% |
| 2025-05-01 | $0.32 | $0.33 | -2.2% | $1.0B | $1.0B | +1.8% |
| 2025-02-13 | $0.45 | $0.48 | -6.1% | $1.1B | $1.1B | +0.4% |
| 2024-10-24 | $0.45 | $0.44 | +2.3% | $994.2M | $990.4M | +0.4% |
| 2024-07-25 | $0.43 | $0.39 | +10.3% | $1.0B | $1.0B | -3.2% |
| 2024-04-25 | $0.32 | $0.27 | +18.5% | $921.0M | $909.9M | +1.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66B | 4.03B | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B | 1.03B | 718.50M | 573.30M | 402.00M | 259.20M |
| Net Income | 836.30M | 576.20M | 541.50M | 341.20M | 216.90M | 493.60M | 101.10M | (127.10M) | (50.20M) | (65.60M) | (57.60M) | (22.40M) |
| EPS | 2.14 | 1.46 | 1.44 | 0.88 | 0.56 | 1.31 | 0.28 | -0.36 | -0.15 | -0.20 | -0.18 | -0.07 |
| Total Assets | 6.34B | 6.48B | 6.26B | 5.39B | 4.93B | 4.29B | 2.40B | 1.92B | 904.10M | 402.80M | 292.00M | 184.60M |
| Total Debt | 1.39B | 2.59B | 2.59B | 2.15B | 2.16B | 1.84B | 1.16B | 1.02B | 334.30M | 6.70M | 2.30M | 4.60M |
| Cash & Equivalents | 917.70M | 606.10M | 566.30M | 642.30M | 1.05B | 817.60M | 446.20M | 1.14B | 441.50M | 94.50M | 86.10M | 71.80M |
| Operating Cash Flow | 1.44B | 989.50M | 748.50M | 669.50M | 442.50M | 475.60M | 314.50M | 123.20M | 92.00M | 56.20M | 49.00M | 23.60M |
| Free Cash Flow | 1.08B | 630.70M | 511.90M | 304.70M | 53.30M | 276.60M | 134.50M | 56.10M | 26.00M | 500,000 | 15.70M | 7.40M |
| FCF per Share | 2.76 | 1.56 | 1.33 | 0.78 | 0.14 | 0.73 | 0.37 | 0.16 | 0.08 | 0.00 | 0.05 | 0.02 |
| Book Value | 2.75B | 2.10B | 2.07B | 2.13B | 2.04B | 1.83B | 882.60M | 663.30M | 419.40M | 283.80M | 221.20M | 140.20M |
| Cash & ST Investments | 2.00B | 2.58B | 2.72B | 2.46B | 2.73B | 2.71B | 1.53B | 1.39B | 548.60M | 123.70M | 115.20M | 83.60M |
| ROC Equity | 0.30 | 0.27 | 0.26 | 0.16 | 0.11 | 0.27 | 0.11 | -0.19 | -0.12 | -0.23 | -0.26 | -0.16 |